High-Density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Chi, Pei Dong ^a   Liu, Wen ^a   Chen, Hao ^a   Zhang, Jing Ping ^a   Lin, Yuehao ^a   Zheng, Xin ^a   Liu, Wanli ^a   Dai, Shuqin ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR MARKER; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPID;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; SMOKING; SURVIVAL RATE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CHOLESTEROL, HDL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LIPIDS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84898738879     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091080     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. (Pubitemid 351521864)
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592. (Pubitemid 46359643)
3. Brower V (2009) Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst 101: 11-13.
4. Fiorenza AM, Branchi A, Sommariva D (2000) Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 30: 141-145. (Pubitemid 32151973)
5. Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, et al. (2000) Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med 6: 307-311.
6. Alexopoulos CG, Blatsios B, Avgerinos A (1987) Serum lipids and lipoprotein disorders in cancer patients. Cancer 60: 3065-3070. (Pubitemid 18005885)
7. Umeki S (1993) Decreases in serum cholesterol levels in advanced lung cancer. Respiration 60: 178-181.
8. Moorman PG, Hulka BS, Hiatt RA, Krieger N, Newman B, et al. (1998) Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev 7: 483-488. (Pubitemid 28354111)
9. Dessi S, Batetta B, Pulisci D, Spano O, Anchisi C, et al. (1994) Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer 73: 253-258. (Pubitemid 24030598)
10. Cruz PM, Mo H, McConathy WJ, Sabnis N, Lacko AG (2013) The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol 4: 119.
11. Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL (2011) Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 226: 2316-2328.
12. Jeon JH, Kim SK, Kim HJ, Chang J, Ahn CM, et al. (2010) Lipid raft modulation inhibits NSCLC cell migration through delocalization of the focal adhesion complex. Lung Cancer 69: 165-171.
13. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, et al. (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18: 2814-2821.
14. Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, et al. (2013) High-density lipoprotein and prostate cancer: an overview. J Epidemiol 23: 313-319.
15. Esteve E, Ricart W, Fernandez-Real JM (2005) Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 24: 16-31.
16. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867. (Pubitemid 36019639)
17. Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T, Janowska J, Szulc A, et al. (2003) Hyperlipidaemias and serum cytokines in patients with coronary artery disease. Acta Cardiol 58: 9-15. (Pubitemid 36433065)
18. van Exel E, Gussekloo J, de Craen AJ, Frolich M, Bootsma-Van Der Wiel A, et al. (2002) Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 51: 1088-1092. (Pubitemid 34438354)
19. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F (1998) Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97: 1029-1036.
20. Wallberg-Jonsson S, Dahlen G, Johnson O, Olivecrona G, Rantapaa-Dahlqvist S (1996) Lipoprotein lipase in relation to inflammatory activity in rheumatoid arthritis. J Intern Med 240: 373-380. (Pubitemid 27008410)
21. Lim U, Gayles T, Katki HA, Stolzenberg-Solomon R, Weinstein SJ, et al. (2007) Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. Cancer Res 67: 5569-5574. (Pubitemid 46997300)
22. Levy E, Gurbindo C, Lacaille F, Paradis K, Thibault L, et al. (1993) Circulating tumor necrosis factor-alpha levels and lipid abnormalities in patients with cystic fibrosis. Pediatr Res 34: 162-166. (Pubitemid 23207200)
23. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, et al. (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74: 1045-1052.
24. Cheng X, Li J, Zhang Z (1998) [Analysis of basic data of the study on prevention and treatment of COPD and chronic cor pulmonale]. Zhonghua Jie He He Hu Xi Za Zhi 21: 749-752.
25. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol 4: 198-203. (Pubitemid 41697502)
26. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474.
27. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, et al. (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714. (Pubitemid 47357522)
28. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421.
29. Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107: 391-397.
30. Kucharska-Newton AM, Rosamond WD, Schroeder JC, McNeill AM, Coresh J, et al. (2008) HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study. Lung Cancer 61: 292-300.
31. Guo E, Chen L, Xie Q, Chen J, Tang Z, et al. (2007) Serum HDL-C as a potential biomarker for nodal stages in gastric cancer. Ann Surg Oncol 14: 2528-2534. (Pubitemid 47389563)
32. von Eckardstein A, Hersberger M, Rohrer L (2005) Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care 8: 147-152. (Pubitemid 40289474)
33. Lewis GF, Rader DJ (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96: 1221-1232. (Pubitemid 40962099)
34. Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, et al. (2012) HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther 11: 1311-1319.
35. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, et al. (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 107: 19997-20002.
36. Baker M (2004) EGFR inhibitors square off at ASCO. Nat Biotechnol 22: 641.
37. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10: 461-466. (Pubitemid 41266326)
38. Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, et al. (2008) U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 14: 1296-1302. (Pubitemid 351413907)
39. Italiano A, Besse B, Planchard D, Soria JC (2007) [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]. Bull Cancer 94: F177-188.
40. Gazdar AF (2010) Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev 29: 37-48.
41. Boutsikou E, Kontakiotis T, Zarogoulidis P, Darwiche K, Eleptheriadou E, et al. (2013) Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Targets Ther 6: 125-134.
42. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, et al. (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29: 2866-2874.
43. Engels EA (2008) Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 8: 605-615.
44. Peto R, Darby S, Deo H, Silcocks P, Whitley E, et al. (2000) Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 321: 323-329. (Pubitemid 30496873)
45. Tietge UJ, Maugeais C, Lund-Katz S, Grass D, deBeer FC, et al. (2002) Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol 22: 1213-1218. (Pubitemid 34764876)
46. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, et al. (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 24: 5216-5222. (Pubitemid 46631365)
47. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. (2005) The double jeopardy of HDL. Ann Med 37: 173-178. (Pubitemid 40780434)